Biovail Corporation Receives Approval For Wellbutrin(R) XL To Treat Depression In Canada

TORONTO--(BUSINESS WIRE)--Jan. 17, 2006--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that the Therapeutic Products Directorate Canada (TPD) has issued a Notice of Compliance (NOC) for 150mg and 300mg tablet strengths of Wellbutrin(R) XL, a once-daily, extended-release formulation of bupropion hydrochloride (HCl) for the treatment of major depressive illness in adults.

MORE ON THIS TOPIC